We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The firm recently secured denial of a preliminary injunction against its client, Servona GmbH (“Servona”), a leading supplier of medical products in Germany
In Warner Chilcott Labs. Ireland Ltd. v. Mylan Pharms. Inc., No. 2011-1611 (Fed. Cir. Dec. 12, 2011), the Federal Circuit vacated a preliminary injunction entered by the U.S. District Court for the District of New Jersey to prevent Mylan from launching a generic version of 150 mg Doryx, which is the branded name for the doxycycline hyclate delayed-release tablets sold by plaintiffs Warner Chilcott and Mayne Pharma International (the “Plaintiffs”
